Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCy: Reduced PTCy Dose in Haploidentical HSCT
NCT07193420Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2026
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07193420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193420.